Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ublituximab plus umbralisib in participants previously enrolled in a related protocol; the trial is terminated with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ublituximab (ublituximab)
• umbralisib

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2023-06-22